What's New 2025
-
New
Position Paper "Toward Advancing and Increasing the Value of Medical and Pharmaceutical Products Co-Created with Patients" - Patient-Reported Outcome (PRO) Evaluation as a Permanent
is now available. -
New
Position Paper "Survey of Domestic Emerging Pharmaceutical Companies (EBPs) with Developed Products" is now available.
is now available. -
New
Policy Research Institute News No.76 is now available.
-
The article on the Institute for Pharmaceutical Industry Policy Studies was published in "Toward the Era of Co-Creation," a series of articles by the Pharmaceutical Manufacturers' Association of Japan (PMAJ) Committee in the Nikkan Yakugyo.
(17) "Contributing to the Study of Industry Issues with Evidence," Dr. Yamada, Director of the Pharmaceutical Industry Policy Institute
Please refer to the link for details. -
Position Paper "Survey on EBP-derived drugs in the U.S.
A Comparison of Biotech and Small Molecule Products
is now available. -
Position Paper "Survey Report of Pharmaceutical Companies on Utilization of Public Databases, etc.
from Policy Research Institute News No.75
is now available. -
Policy Research Institute News No.75 is now available.
-
Dr. Sadao Nagaoka, former director and current research advisor of the Pharmaceutical and Industrial Policy Research Institute, received the 5th
Dr. Sadao Nagaoka was awarded "The 5th Nakamura Takahide Award" by the Japan Statistical Society.
The reason for the award is that Dr. Nagaoka's achievements in innovation research using statistical analysis and his pioneering work have been highly evaluated internationally.
The reason for the award is that Dr. Nagaoka's innovation research results and pioneering work using statistical analysis have been highly evaluated internationally.
We congratulate Dr. Nagaoka for receiving this award. Please refer to the link for details. -
The overseas paper submitted by IPSJ has been published.
Cost and Duration of Clinical Trials in Drug Development by Japanese Pharmaceutical Companies
(Research Paper No.82 "The State of Pharmaceutical R&D: R&D Duration, Probability of Success, and R&D Costs Based on a Questionnaire Survey") -
Research Institute Profile page has been updated.
-
Research Paper No.85 is now available.
-
Policy Research Institute News No.74 is now available.
-
Position Paper "A Study on the NHI Calculation Rules for Evaluating the Value of Drugs
Position Paper No.3 "Issues of the Evaluation System in the Transition of the Value of Pharmaceuticals" is now available.
is now available.
